" class="no-js "lang="en-US"> bit.bio Launches New Custom Disease Model Cells Offering
Thursday, June 08, 2023

bit.bio Launches New Custom Disease Model Cells Offering, Advancing Disease Research and Drug Discovery

bit.bio, a cell coding company, has launched its new Custom ioDisease Model Cells offering. This offering allows scientists to commission their disease-relevant mutation of interest in bit.bio’s human induced pluripotent stem cell (iPSC)-derived cells powered by opti-ox technology.

The disease-relevant mutation is engineered into bit.bio’s human ioWild Type cells using CRISPR/Cas9 gene editing. As disease model cells come from an identical human genetic background to ioWild Type cells, any experimental differences observed between the wild type and the disease model can be confidently attributed to the effects caused by the disease-specific mutations.

bit.bio’s cells are precision reprogrammed by opti-ox, which enables the manufacturing of any human cell type at scale with precision and consistency. These key features make the models ideally suited to screening applications for early drug discovery as well as for fundamental research. Scientists receive defined, consistent, ready-to-use cells, empowering them to investigate the impact of their mutation in a human context.

Due to a lack of standardised, easy to use and readily accessible human cell models, scientists have relied on animal models and cell lines that differ considerably from human biology. iPSC-derived cells from patients offer a human model for disease research, but sourcing them with the disease-specific mutation of interest can be a complex and time-consuming process. These cells also often lack standardisation and optimised, fast protocols, making it difficult to generate consistent data and scalable disease models. This offering provides scientists with a powerful tool to overcome these limitations.

Dr Mark Kotter, CEO of bit.bio, expressed his excitement about the new offering, “With this new offering, we can cater to the vast diversity of scientific research into human diseases, providing scientists with the models they need to study their specific interests. Our custom disease cell model offering aligns with bit.bio’s mission to democratise access to human cells for research and drug discovery.”

bit.bio has partnered with leading contract research organisation Charles River Laboratories to provide disease models in their early drug discovery programmes. Models were developed for Duchenne muscular dystrophy, Huntington’s, amyotrophic lateral sclerosis and frontotemporal dementia, which have now been successfully integrated into their phenotypic screening workflows. The cells are now available off the shelf as part of bit.bio’s ioDisease Model Cells portfolio.

Dr Paul Morrill, Chief Business Officer, bit.bio said, “Human cells are key to disease research, drug discovery, and clinical translation. However, traditional methods of producing human cells have long, laborious, protocols that often result in heterogenous cell populations that can lead to significant data variability. With this customised offering, we can provide robust, standardised tools for research and drug discovery. This gives researchers a unique method to gain valuable insights into disease mechanisms and assess the efficacy of potential drugs for treatment. We are already seeing demand for our Custom ioDisease Model Cells from industry and it will be particularly exciting to understand how they will use their models to gain new insights and treatments for conditions where patients are waiting for life changing breakthroughs.”

  1. Aegis Life Awarded Grant to Develop DNA-encoded Antibodies Against Infectious Diseases Read more
  2. New “AI Doctor” Predicts Hospital Readmission and Other Health Outcomes Read more
  3. Axol Bioscience Collaborates with StrataStem to Deliver Stem Cell-Based ‘Clinical Trial in a Dish’ for Alzheimer’s Disease Read more
  4. MedTech Innovator Asia Pacific Names 24 Startups to Annual Accelerator Read more
  5. XNK Therapeutics Appoints Hugo Petit as Chief Financial Officer Read more